论文部分内容阅读
回顾性分析了武汉地区部分医院近５年来溶栓或非溶栓治疗对４５５例急性心肌梗塞（ＡＭＩ）患者病死率的影响。结果显示静脉给予尿激酶可降低ＡＭＩ近期病死率。尿激酶剂量＞９０万Ｕ组的病死率比＜９０万Ｕ组低，早期溶栓比延迟溶栓的疗效好，说明合理使用尿激酶静脉溶栓，可提高ＡＭＩ的存活率，改善病人的预后。
We retrospectively analyzed the impact of thrombolytic or non-thrombolytic therapy in 455 patients with acute myocardial infarction (AMI) in some hospitals in Wuhan in the past five years. The results showed that intravenous administration of urokinase can reduce the recent mortality of AMI. Urokinase dose> 90 million U group of mortality than <90 million U group, early thrombolysis delayed thrombolytic effect than good, indicating that the rational use of intravenous thrombolytic urokinase can improve the survival rate of AMI and improve the patient’s prognosis .